Amneal Pharmaceuticals (AMRX) Competitors $8.07 +0.32 (+4.13%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMRX vs. ITCI, ROIV, ASND, RVMD, LNTH, NUVL, LEGN, BPMC, ELAN, and CYTKShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health Cytokinetics Amneal Pharmaceuticals (NASDAQ:AMRX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Do insiders & institutionals have more ownership in AMRX or ITCI? 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in AMRX or ITCI? Intra-Cellular Therapies received 506 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 93.75% of users gave Amneal Pharmaceuticals an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25%Intra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Which has more volatility and risk, AMRX or ITCI? Amneal Pharmaceuticals has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Is AMRX or ITCI more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Intra-Cellular Therapies -14.07%-9.93%-8.38% Does the media refer more to AMRX or ITCI? In the previous week, Intra-Cellular Therapies had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Intra-Cellular Therapies and 3 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.26 beat Intra-Cellular Therapies' score of 0.65 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, AMRX or ITCI? Amneal Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.68B0.93-$83.99M-$0.68-11.87Intra-Cellular Therapies$612.78M15.04-$139.67M-$0.87-99.95 Do analysts rate AMRX or ITCI? Amneal Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 23.92%. Intra-Cellular Therapies has a consensus price target of $97.23, suggesting a potential upside of 11.81%. Given Amneal Pharmaceuticals' higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 SummaryAmneal Pharmaceuticals beats Intra-Cellular Therapies on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.50B$6.86B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-11.8710.75130.2217.53Price / Sales0.93287.791,246.14139.51Price / Cash6.0056.6541.2337.95Price / Book115.295.394.884.92Net Income-$83.99M$152.04M$119.65M$225.78M7 Day Performance-0.37%-4.32%16.62%-1.56%1 Month Performance-3.12%2.80%16.34%6.68%1 Year Performance50.84%17.30%35.38%22.48% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals2.205 of 5 stars$8.07+4.1%$10.00+23.9%+55.5%$2.50B$2.68B-11.877,700Positive NewsITCIIntra-Cellular Therapies4.1678 of 5 stars$84.70+2.0%$97.23+14.8%+32.9%$8.98B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.07+1.9%$17.93+48.5%+8.9%$8.79B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$135.90+4.6%$191.77+41.1%+16.0%$8.24B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.93-0.2%$63.67+41.7%+69.6%$7.56B$11.58M-12.54443Positive NewsLNTHLantheus4.3734 of 5 stars$94.77+1.9%$130.00+37.2%+21.9%$6.59B$1.50B15.42834Positive NewsNUVLNuvalent2.3475 of 5 stars$86.67-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.17-5.6%$81.54+145.8%-43.4%$6.06B$520.18M-36.971,800BPMCBlueprint Medicines2.9172 of 5 stars$95.31+2.3%$122.11+28.1%+9.7%$6.05B$434.42M-45.28640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.19+0.7%$16.75+37.4%-10.5%$6.03B$4.45B30.259,300CYTKCytokinetics3.9886 of 5 stars$49.18+1.1%$83.93+70.7%+32.5%$5.80B$3.22M-9.04250 Related Companies and Tools Related Companies ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors NUVL Competitors LEGN Competitors BPMC Competitors ELAN Competitors CYTK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
